Results 211 to 220 of about 158,526 (239)
Some of the next articles are maybe not open access.
The Lancet, 2006
Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding of the molecular pathogenesis of the hallmarks of the disease--ie, plaques, composed of amyloid beta (Abeta), and tangles, composed of hyperphosphorylated tau.
Kaj, Blennow +2 more
openaire +2 more sources
Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding of the molecular pathogenesis of the hallmarks of the disease--ie, plaques, composed of amyloid beta (Abeta), and tangles, composed of hyperphosphorylated tau.
Kaj, Blennow +2 more
openaire +2 more sources
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2018
Alzheimer's disease (AD) is a serious medical and social problem of our time, while remaining the most common cause of dementia in the elderly. The leading symptom in the clinical picture of the disease is a progressive loss of memory with further development of behavioral disorders.
O A, Kicherova, L I, Reikhert
openaire +2 more sources
Alzheimer's disease (AD) is a serious medical and social problem of our time, while remaining the most common cause of dementia in the elderly. The leading symptom in the clinical picture of the disease is a progressive loss of memory with further development of behavioral disorders.
O A, Kicherova, L I, Reikhert
openaire +2 more sources
Nature Reviews Disease Primers, 2015
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years) and an average clinical duration of 8-10 years. The disease has an estimated prevalence of 10-30% in the population >65 years of age with an incidence of 1-3%.
Colin L, Masters +5 more
openaire +4 more sources
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years) and an average clinical duration of 8-10 years. The disease has an estimated prevalence of 10-30% in the population >65 years of age with an incidence of 1-3%.
Colin L, Masters +5 more
openaire +4 more sources
Annual Review of Medicine, 1985
Significant progress has been made in identifying changes in cholinergic, monoaminergic, and peptidergic neurotransmitter systems in the brains of individuals with Alzheimer's disease. Moreover, neurobiological approaches are beginning to reveal the relationships between these neurotransmitter abnormalities and histological hallmarks of the disease, i ...
D L, Price +2 more
+7 more sources
Significant progress has been made in identifying changes in cholinergic, monoaminergic, and peptidergic neurotransmitter systems in the brains of individuals with Alzheimer's disease. Moreover, neurobiological approaches are beginning to reveal the relationships between these neurotransmitter abnormalities and histological hallmarks of the disease, i ...
D L, Price +2 more
+7 more sources
The Lancet, 2019
Alzheimer's disease (AD) dementia refers to a particular onset and course of cognitive and functional decline associated with age together with a particular neuropathology. It was first described by Alois Alzheimer in 1906 about a patient whom he first encountered in 1901.
Jose A, Soria Lopez +2 more
openaire +4 more sources
Alzheimer's disease (AD) dementia refers to a particular onset and course of cognitive and functional decline associated with age together with a particular neuropathology. It was first described by Alois Alzheimer in 1906 about a patient whom he first encountered in 1901.
Jose A, Soria Lopez +2 more
openaire +4 more sources
Comprehensive Therapy, 2007
Alzheimer's disease is the most prevalent form of dementia. There are significant efforts underway to elucidate the pathogenesis of this disease and to find ways to lessen the impact of the symptoms. This paper summarizes current knowledge regarding the diagnosis and treatment of the disorder.
openaire +2 more sources
Alzheimer's disease is the most prevalent form of dementia. There are significant efforts underway to elucidate the pathogenesis of this disease and to find ways to lessen the impact of the symptoms. This paper summarizes current knowledge regarding the diagnosis and treatment of the disorder.
openaire +2 more sources
British Dental Journal, 1990
Alzheimer's disease (AD) is a debilitating and progressive disease that can affect dental practice in a number of ways. Not only will increasing numbers of AD patients be treated by dentists in the future but the dentist and members of his family may also be unfortunate enough to become affected. In the United Kingdom, nearly 10% of the population over
G H, Moody, J R, Drummond, J P, Newton
openaire +2 more sources
Alzheimer's disease (AD) is a debilitating and progressive disease that can affect dental practice in a number of ways. Not only will increasing numbers of AD patients be treated by dentists in the future but the dentist and members of his family may also be unfortunate enough to become affected. In the United Kingdom, nearly 10% of the population over
G H, Moody, J R, Drummond, J P, Newton
openaire +2 more sources
Maturitas, 1999
This article reviews the clinical and neuropathological features of Alzheimer's disease, its known genetic and non-genetic risk factors, procedures used to make the diagnosis and rule out other reversible and non-reversible forms of dementia, and the treatment strategies used to help patients and their families cope with the problem.
E M, Reiman, R J, Caselli
openaire +2 more sources
This article reviews the clinical and neuropathological features of Alzheimer's disease, its known genetic and non-genetic risk factors, procedures used to make the diagnosis and rule out other reversible and non-reversible forms of dementia, and the treatment strategies used to help patients and their families cope with the problem.
E M, Reiman, R J, Caselli
openaire +2 more sources
2018
Alzheimer disease neuropathology is characterized by the extracellular accumulation of Aβ peptide and intracellular aggregation of hyperphosphorylated tau. With the progression of the disease, macroscopic atrophy affects the entorhinal area and hippocampus, amygdala, and associative regions of the neocortex. The locus coeruleus is depigmented.
Ana Laura, Calderon-Garcidueñas +1 more
openaire +2 more sources
Alzheimer disease neuropathology is characterized by the extracellular accumulation of Aβ peptide and intracellular aggregation of hyperphosphorylated tau. With the progression of the disease, macroscopic atrophy affects the entorhinal area and hippocampus, amygdala, and associative regions of the neocortex. The locus coeruleus is depigmented.
Ana Laura, Calderon-Garcidueñas +1 more
openaire +2 more sources